Erasca

Erasca's approach is modality-agnostic, including small molecules, large molecules, and protein degraders—alone and in combinations across multiple tumor types— to selectively and potently inhibit or degrade critical in-pathway and escape-route signaling nodes of the RAS/MAPK pathway.